4CPS-066 Biological treatments used to treat hidradenitis suppurativa in a tertiary hospital

Background and ImportanceHidradenitis suppurativa (HS) is a chronic inflammatory skin disease which causes painful inflamed lesions in the apocrine gland-bearing areas of the body, with high impact on patients’ quality of life. Treatment is based on a combination of surgical and medical therapies, w...

Full description

Saved in:
Bibliographic Details
Published in:European journal of hospital pharmacy. Science and practice 2023-03, Vol.30 (Suppl 1), p.A45-A46
Main Authors: Mestre Ribot, MM, González García, R, Martín Conde, MT, Roma Mora, JR, Arranz Pascual, N, Soy Muner, D
Format: Article
Language:English
Subjects:
Biological products
Conflicts of interest
Section 4: Clinical pharmacy services
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and ImportanceHidradenitis suppurativa (HS) is a chronic inflammatory skin disease which causes painful inflamed lesions in the apocrine gland-bearing areas of the body, with high impact on patients’ quality of life. Treatment is based on a combination of surgical and medical therapies, within biological agents play a key role. Adalimumab is currently the only biologic approved, what leads to use off-label biological treatments when adalimumab fails.Aim and ObjectivesOur objective is to analyse the prescription of biological treatments, dosages used and adherence in a tertiary hospital to treat HS.Material and MethodsMedical charts of patients treated with biological drugs for HS where reviewed. Demographic features (sex, age, weight, height, smoking status), clinical stage (hurley score) and biological treatment used –including dosages, number of previous lines and adherence– were recorded.ResultsForty-one patients were included. Median age was 43 (IQR 30-52) and median body mass index was 27 (IQR 24-33). Nineteen out of 41 had a hurley score of 3 (H3) and 22 had a hurley score of 2 (H2). Twenty-seven patients were on adalimumab, including all patients H2 and 5 patients H3. Sixteen out of 27 were on 40 mg q.wk, and 11 were on 80 mg q.wk. The rest of H3 patients were on: infliximab 10 mg/kg (4), infliximab 7.5 mg/kg q.4.wk (1), subcutaneous infliximab 240 mg q.wk (2), brodalumab 210 mg q.wk (3), tocilizumab 8 mg/kg q.4.wk (1), guselkumab 100 mg q.4.wk (2), and ustekinumab 90 mg q.8.wk (1). Median previous lines in H3 patients were 1 (IQR 1-3), and five of H3 patients does not show a satisfactory improvement with current treatment. Only 3 patients showed an adherence
ISSN:2047-9956
2047-9964
DOI:10.1136/ejhpharm-2023-eahp.96